Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations
Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.